A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients with Essential Hypertension and Type 2 Diabetes in Asia
Table 1
Key demographic and baseline characteristics (safety analysis set).
Parameter
Number of patients by BHT status groups (%)
Switched
Add-on
Overall
N
289
90
380
Female, n (%)
155 (53.6)
42 (46.7)
197 (51.8)
Age, years, mean (SD)
61.3 (9.95)
62.5 (9.17)
61.6 (9.77)
Age category, years, n (%)
≥65 to <75
116 (40.1)
43 (47.8)
159 (41.8)
<65
173 (59.9)
47 (52.2)
221 (58.2)
≥45 to <65
151 (52.2)
42 (46.7)
194 (51.1)
<45
22 (7.6)
5 (5.6)
27 (7.1)
Body weight, kg, mean (SD)
72.0 (15.71)
72.1 (13.05)
72.0 (15.07)
BMI, kg/m2, mean (SD)
27.6 (4.51)
27.8 (3.85)
27.6 (4.35)
BMI category, kg/m2, n (%)
<23
39 (13.5)
10 (11.1)
49 (12.9)
≥23
244 (84.4)
80 (88.9)
325 (85.5)
<30
202 (69.9)
65 (72.2)
268 (70.5)
≥30
81 (28.0)
25 (27.8)
106 (27.9)
HbA1c, mmoL/moL, mean (SD)
7.00 (0.901)
7.01 (0.796)
7.00 (0.875)
Baseline antihypertensive treatment, n (%)∗
ACE inhibitor or ARB
198 (68.5)
4 (4.4)
202 (53.2)
CCB
94 (32.5)
18 (20.0)
112 (29.5)
Thiazide
30 (10.4)
0
30 (7.9)
Other
52 (18.0)
68 (75.6)
121 (31.8)
Clinical sitting SBP, mm Hg, mean (SD)
152.2 (11.58)
152.7 (12.08)
152.3 (11.68)
Clinical sitting DBP, mm Hg, mean (SD)
84.8 (9.87)
84.0 (8.94)
84.6 (9.65)
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BHT, baseline hypertension treatment; BMI, body mass index; CCB, calcium channel blocker; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin; SBP, systolic blood pressure; SD, standard deviation. One patient from the treatment-naïve group was considered only in the overall analysis. ∗The sum of all treatments exceeds 380 as a single patient may have been receiving up to 2 antihypertensive treatments at baseline.
